Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Enteryx

This article was originally published in The Gray Sheet

Executive Summary

Gastroesophageal reflux disease treatment gains newly assigned CPT code, permitting reimbursement under the hospital outpatient prospective payment system in 2004. The liquid polymer earned FDA approval in April (1"The Gray Sheet" April 28, 2003, p. 6)...

You may also be interested in...

Enteryx reimbursement

Results from Boston Scientific's ongoing U.S. and European gastrointestinal reflux disease treatment randomized placebo studies will be used to obtain private payor coverage. The 60-patient European study completed enrollment March 3, and enrollment for the 120-patient U.S. study is expected to conclude this summer. Both trials feature equal-sized treatment and placebo arms, with one-, three- and 12-month follow up. Enteryx recently received a CPT code for Medicare outpatient payment (1"The Gray Sheet" Nov. 24, 2003, In Brief)...

Boston Scientific Enteryx GERD Device Clears FDA With Limited Indication

Patients who respond to pharmacological treatments for gastroesophageal reflux disease (GERD) have a new therapeutic alternative in Boston Scientific's Enteryx injectable treatment system

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts